The Effect of Citrus Extract Administration on Markers of Oxidative Stress in Elderly Subjects

Maastricht University Medical Center1 site in 1 country37 target enrollmentSeptember 28, 2018

ConditionsElderly

Overview

Phase: N/A
Intervention: Not specified
Conditions: Elderly
Sponsor: Maastricht University Medical Center
Enrollment: 37
Locations: 1
Primary Endpoint: Oxidative stress
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This randomized, cross-over, double-blind, placebo-controlled trial aims to determine the effects of daily administration of citrus extract over a period of 4 weeks on markers of oxidative stress in elderly.

Registry

clinicaltrials.gov

Start Date

September 28, 2018

End Date

October 1, 2019

Last Updated

6 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Maastricht University Medical Center

Responsible Party

Principal Investigator

Yala Stevens

MSc.

Maastricht University Medical Center

Eligibility Criteria

Inclusion Criteria

•Healthy individuals
•Age 70-85 years
•BMI \< 30 kg/m2

Exclusion Criteria

•History or actual status of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol.
•Disease with a life expectancy shorter than 5 years
•Institutionalized (e.g. hospital or nursing home).
•Subjects with abnormalities in haematology which may interfere with the endpoints of the study (to be decided by the principle investigator)
•Use of drugs or hormones within 3 months prior to the start of the study which may interfere with the endpoints of the study (to be decided by the principle investigator)
•Self-admitted Inflammation, (viral) infection (e.g. HIV or hepatitis B)
•Subjects with an autoimmune disease (e.g. Rheumatoid arthritis)
•Subjects with intestinal disorders which may interfere with the endpoints of the study (to be decided by the principle investigator)
•Use of immunosuppressive drugs within 3 months prior to the start of the study
•Use of medication (e.g. NSAIDs), antibiotics or corticosteroids which may interfere with the endpoints of the study (to be decided by the principle investigator)